Ken Griffin Delcath Systems, Inc. Transaction History

Citadel Advisors LLC

$618 Billion
Q3 2025

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Delcath Systems, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 449,315 shares of DCTH stock, worth $4.01 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

449,315

Previous 803,208 44.06%

Holding current value

$4.01 Million

Previous $10.9 Million 55.78%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	SELL	$10.01 - $12.76 $3.54 Million - $4.52 Million	-353,893 Reduced 44.06%	449,315 $4.83 Million
Q2 2025 Aug 14, 2025	BUY	$10.39 - $18.1 $7.04 Million - $12.3 Million	677,656 Added 539.74%	803,208 $10.9 Million
Q1 2025 May 15, 2025	SELL	$11.43 - $16.45 $1.88 Million - $2.7 Million	-164,049 Reduced 56.65%	125,552 $1.6 Million
Q4 2024 Feb 14, 2025	BUY	$8.32 - $12.64 $1.13 Million - $1.71 Million	135,640 Added 88.1%	289,601 $3.41 Million
Q3 2024 Nov 14, 2024	BUY	$7.36 - $11.0 $7,647 - $11,429	1,039 Added 0.68%	153,961 $1.39 Million

Q2 2024 Aug 14, 2024	BUY	$4.47 - $8.37 $491,758 - $920,808	110,013 Added 256.39%	152,922 $1.28 Million
Q1 2024 May 15, 2024	SELL	$3.72 - $5.09 $53,106 - $72,664	-14,276 Reduced 24.96%	42,909 $204,000
Q4 2023 Feb 14, 2024	BUY	$2.25 - $4.17 $126,346 - $234,162	56,154 Added 5446.56%	57,185 $237,000
Q3 2023 Nov 14, 2023	SELL	$3.12 - $5.85 $54,107 - $101,450	-17,342 Reduced 94.39%	1,031 $4,000
Q2 2023 Aug 14, 2023	BUY	$5.38 - $7.96 $98,846 - $146,249	18,373 New	18,373 $107,000
Q4 2022 Feb 14, 2023	BUY	$2.59 - $3.71 $62,646 - $89,737	24,188 New	24,188 $87,000

Others Institutions Holding DCTH

# of Institutions

130

Shares Held

13M

Call Options Held

133K

Put Options Held

159K

View Full List

About DELCATH SYSTEMS, INC.

Ticker DCTH
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 8,597,680
Market Cap $76.8M
Description
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling syste...

More about DCTH

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account